콘텐츠로 건너뛰기
Merck

SML0061

Sigma-Aldrich

SAHA

≥98% (HPLC), powder, HDAC inhibitor

동의어(들):

N-hydroxy-N′-phenyl-octanediamide, Suberoylanilide hydroxamic acid, Vorinostat

로그인조직 및 계약 가격 보기

크기 선택

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C14H20N2O3
CAS 번호:
149647-78-9
Molecular Weight:
264.32
MDL number:
MFCD00945317
UNSPSC 코드:
12352200
PubChem Substance ID:
329825127
NACRES:
NA.77

주요 문서

모든 문서 보기
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

제품 이름

SAHA, ≥98% (HPLC)

Quality Level

100

분석

≥98% (HPLC)

양식

powder

색상

white to tan

solubility

DMSO: ≥15 mg/mL

배송 상태

wet ice

저장 온도

−20°C

SMILES string

ONC(=O)CCCCCCC(=O)Nc1ccccc1

InChI

1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

InChI key

WAEXFXRVDQXREF-UHFFFAOYSA-N

유전자 정보

human ... HDAC1(3065), HDAC2(3066), HDAC3(8841), HDAC6(10013)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

애플리케이션

SAHA may be used to study gene regulation, transcription regulation and cell signaling.

생화학적/생리학적 작용

Potent, reversible pan-histone deacetylase (HDAC) inhibitor.
SAHA or Vorinostat facilitates the transcription of genes that result in apoptosis, differentiation and growth arrest. It has been observed to give beneficial results in lymphoma but not in solid tumors.
Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a potent, reversible pan-histone deacetylase (HDAC) inhibitor. It inhibits both class I and class II HDACs, altering gene transcription and inducing cell cycle arrest and/or apoptosis in a wide variety of transformed cells.

특징 및 장점

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

픽토그램

Health hazard
GHS08

신호어

Danger

유해 및 위험 성명서

H341,H360

Hazard Classifications

Muta. 2 - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
106M4705V
035M4769V
113M4752V
042M4740V
061M4742V

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Sarah W Gordon et al.
American journal of clinical oncology, 42(8), 649-654 (2019-07-16)
Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma. Patients received vorinostat (200
Robert W Robey et al.
Molecular pharmaceutics, 8(6), 2021-2031 (2011-09-09)
The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell
Gloria Manzotti et al.
Journal of experimental & clinical cancer research : CR, 38(1), 346-346 (2019-08-10)
RUNX2 is a Runt-related transcription factor required during embryogenesis for skeletal development and morphogenesis of other organs including thyroid and breast gland. Consistent evidence indicates that RUNX2 expression is aberrantly reactivated in cancer and supports tumor progression. The mechanisms leading
Sachith Mettananda et al.
Scientific reports, 9(1), 11649-11649 (2019-08-14)
β-Thalassaemia is one of the most common monogenic diseases with no effective cure in the majority of patients. Unbalanced production of α-globin in the presence of defective synthesis of β-globin is the primary mechanism for anaemia in β-thalassaemia. Clinical genetic
Weiwei Yu et al.
British journal of pharmacology, 174(20), 3608-3622 (2017-07-28)
Intrinsic and/or acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly occurs in patients with non-small-cell lung cancer (NSCLC). Here, we developed a combined therapy of histone deacetylase inhibition by a novel HDAC inhibitor, YF454A, with
모든 관련된 서류 보기

문서

Autophagy in Cancer Promotes Therapeutic Resistance

We presents an article on Autophagy in Cancer Promotes Therapeutic Resistance

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

관련 콘텐츠

유전자 조절 연구를 위한 생체 활성 저분자

당사는 유전자 조절 연구 분야에서 표적 식별 및 검증을 위해 전사 인자 조절인자, 염색질 변형 효소 억제제, 작용제/길항제와 같은 여러 저분자 연구 툴을 제공합니다. 이러한 연구 툴 제품군은 아래에 나와 있습니다.

Autophagy in Cancer Promotes Therapeutic Resistance

Autophagy in Cancer

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.